Monoclonal antibodies are the workhorse molecules of the immunotherapy field. These antibodies have been engineered to bind to immune system components and redirect immune responses to kill tumor cells, dial down autoimmune responses, or enhance the effects of other treatments. Much of the work behind production of monoclonal antibodies is rooted in the production of hybridomas, which involves identifying antigen-specific plasma/plasmablast cells (ASPCs) that produce antibodies specific to an antigen of interest and fusing these cells with myeloma cells. These fused hybridoma cell lines can be grown in large-scale culture and produce a single type of (monoclonal) antibody indefinitely under the correct conditions. The ASPC selection process can be time consuming and unpredictable, but recent advances in monoclonal antibody screening that use flow cytometry are making this process faster and more efficient.Read the full article »
Data is the cornerstone of the drug development and clinical trial processes and is critical to determining which candidates move forward. Currently, many drugs and biologics under development, operate by altering the immune system, and flow cytometry is a widely used technique for gathering a wide range of data about the immune response. Flow cytometry can be performed in full compliance with Good Laboratory Practice (GLP) standards, which make it an ideal tool for pre-clinical and clinical studies.Read the full article »
Immunophenotyping is a type of flow cytometry-based analysis in which cells are stained with fluorescently-conjugated antibodies for specific surface and intracellular molecules that define different immune cell populations. Immunophenotyping has been widely used for decades since the advent of cytometers that can detect four colors, and today’s state-of-the-art cytometers allow for concurrent immunophenotypic analysis of numerous cell subsets.
Immunophenotyping has been critical to immuno-oncology research because it allows researchers to monitor changes in the immune system, including potent anti-tumor responses or unexpected off-target responses.Read the full article »